# An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy

> **NCT05540964** · — · UNKNOWN · sponsor: **American Gene Technologies International Inc.** · enrollment: 7 (estimated)

## Conditions studied

- HIV

## Interventions

- **OTHER:** Antiretroviral Therapy Interruption(ATI)

## Key facts

- **NCT ID:** NCT05540964
- **Lead sponsor:** American Gene Technologies International Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-19
- **Primary completion:** 2025-07-19
- **Final completion:** 2025-07-19
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2022-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05540964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05540964, "An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05540964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*